| Trial ID: | L7045 |
| Source ID: | NCT03190798
|
| Associated Drug: |
Canagliflozin 300mg
|
| Title: |
Effects of Canagliflozin on Intravascular Volume and Hemodynamics
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2 Diabetes Mellitus|Cardiovascular Diseases
|
| Interventions: |
DRUG: Canagliflozin 300mg|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in Pulmonary capillary wedge pressure (PCWP), The primary efficacy endpoint will be change in PCWP from baseline to end of acute administration monitoring period (6 hours)., 6 hours | Secondary: Change in Pulmonary capillary wedge pressure (PCWP), The key secondary endpoint will be change in PCWP from baseline to 4 weeks., 4 weeks
|
| Sponsor/Collaborators: |
Sponsor: The University of Texas Health Science Center at San Antonio | Collaborators: Janssen Scientific Affairs, LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2017-09-01
|
| Completion Date: |
2018-08-01
|
| Results First Posted: |
|
| Last Update Posted: |
2017-10-12
|
| Locations: |
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03190798
|
